Roivant Sciences Ltd. $ROIV Shares Sold by Stempoint Capital LP

Stempoint Capital LP cut its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 60.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 385,800 shares of the company’s stock after selling 580,898 shares during the quarter. Roivant Sciences comprises 2.0% of Stempoint Capital LP’s holdings, making the stock its 13th biggest position. Stempoint Capital LP’s holdings in Roivant Sciences were worth $10,687,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Edgestream Partners L.P. acquired a new position in shares of Roivant Sciences during the first quarter worth approximately $1,130,000. Janus Henderson Group PLC raised its stake in Roivant Sciences by 6.1% during the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock valued at $85,790,000 after acquiring an additional 177,339 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in Roivant Sciences during the 1st quarter worth $242,000. Amundi increased its holdings in shares of Roivant Sciences by 41.9% during the first quarter. Amundi now owns 1,480,970 shares of the company’s stock valued at $41,023,000 after purchasing an additional 437,506 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Roivant Sciences by 76.1% during the first quarter. EverSource Wealth Advisors LLC now owns 4,433 shares of the company’s stock valued at $123,000 after purchasing an additional 1,916 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director directly owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,055,913 shares of company stock valued at $69,639,633 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Down 2.9%

Shares of NASDAQ ROIV opened at $32.87 on Thursday. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00. The company has a market cap of $23.64 billion, a price-to-earnings ratio of -54.78 and a beta of 1.11. The business has a fifty day simple moving average of $32.48 and a 200-day simple moving average of $28.93.

Analyst Upgrades and Downgrades

Several research firms have commented on ROIV. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. TD Cowen upped their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Citigroup lifted their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Guggenheim raised their target price on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.